Key Highlights
- VedaBio appoints G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science.
- Dr. Robb brings 16 years of R&D expertise in CRISPR-Cas systems, enzyme tools, and RNA biology.
- Dr. Robb previously led CRISPR-Cas efforts at New England Biolabs (NEB).
- His role at VedaBio will drive the commercialization of CRISPR-based molecular detection.
Source: Business Wire
Notable Quotes
- “We are fortunate to have the chance to welcome Brett to the VedaBio team as Senior Scientific Director and Head of CRISPR Science.” — Frédéric Sweeney, Ph.D., President and CEO at VedaBio
- “VedaBio’s CRISPR cascade uniquely removes the need for nucleic acid pre-amplification… expanding possibilities for diagnostic testing.” — G. Brett Robb, Ph.D., Senior Scientific Director and Head of CRISPR Science at VedaBio
SoHC's Take
The appointment of Dr. G. Brett Robb to VedaBio signals a major step forward in the company’s strategic vision to revolutionize molecular diagnostics through CRISPR technology. His proven leadership in CRISPR-Cas systems and RNA product development positions VedaBio to capitalize on its CRISPR Cascade™ platform, which is poised to transform industries with faster, more accurate diagnostics. Dr. Robb’s background in both commercial and research realms will be instrumental in driving product development and positioning VedaBio as a key player in the molecular diagnostics market.
